Results 41 to 50 of about 12,220,634 (288)

Evolution of Phosphodiesterase-5 Inhibitors

The World Journal of Men's Health, 2015
After the launch of sildenafil citrate (Viagra®), the last great invention of the 20th century, in 1998, oral phosphodiesterase (PDE)-5 inhibitors were established as first-line treatment for erectile dysfunction (ED), representing a paradigm shift in the diagnosis and treatment of ED [1].
openaire   +2 more sources

Therapeutic benefits of Phosphodiesterase type 5 inhibitors: A comprehensive review [PDF]

Archives of Pharmaceutical Sciences Ain Shams University
Phosphodiesterase type 5 (PDE5) inhibitors have been widely used to treat erectile dysfunction. This review aims to explore the favorable effects of PDE5 inhibitors in clinical applications beyond their conventional use.
Yasmin Nabil, Yara M. Aboelmagd, Christine Nathan Habib, ٍamar S. Azab   +3 more
doaj   +1 more source

Multi-target Natural and Nature-Inspired Compounds against Neurodegeneration: A Focus on Dual Cholinesterase and Phosphodiesterase Inhibitors

Applied Sciences, 2021
Alzheimer’s disease is a memory-related neurodegenerative condition leading to cognitive impairment. Cholinergic deficit, together with other underlying mechanisms, leads the to onset and progression of the disease.
Giovanni Ribaudo, Maurizio Memo, Alessandra Gianoncelli   +2 more
doaj   +1 more source

Pharmacotherapy of erectile dysfunction: Current standards

Indian Journal of Urology, 2006
Pharmacotherapy is currently the therapeutic option of choice for erectile dysfunction. Comprising mainly intracavernosal injection therapy using alprostadil or alprostadil combined with phentolamine and/or papaverine and oral phosphodiesterase-5 ...
Kew-Kim Chew
doaj   +1 more source

Phosphodiesterase-5 inhibitors tadalafil and sildenafil potentiate nitrergic-nerve mediated relaxations in the bladder vasculature [PDF]

, 2023
Recent studies suggest that lower urinary tract dysfunction may arise due to changes in local perfusion. Phosphodiesterase-5 inhibitors can improve urinary bladder blood flow, although the local mechanisms have not been fully elucidated.
Nilsson, Damian, Sellers, Donna, Chess-Williams, Russ   +2 more
core   +1 more source

Progressive Parkinsonism in PPP2R5D‐Related Neurodevelopmental Disorder

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT PPP2R5D‐related neurodevelopmental disorder (Houge–Janssens syndrome type 1) is a rare autosomal dominant condition characterized by macrocephaly, intellectual disability, and epilepsy. Progressive parkinsonism is an emerging adult phenotype that neurologists should be aware of since timely genetic diagnosis opens the door to disease‐modifying
Katerina Bernardi, Enrique Gonzalez Saez‐Diez, Joshua Rong, Beril Ay, Shabbir Merchant, Kathryn Yang, Darius Ebrahimi‐Fakhari   +6 more
wiley   +1 more source

Glutathione‐Responsive Acyl‐Modifications for Targeted RNA Decaging and Prolonged Protein Synthesis

Angewandte Chemie, EarlyView.
The self‐immolation of disulfide‐based mRNA modifications in response to endogenous glutathione (GSH) promotes a gradual release of translatable mRNA within the cell, leading to improved nuclease resistance, tunable release properties, and a significant increase (up to 600%) of target protein production over time. This strategy offers an exciting proof
Mary E. Flood, Sathishkumar Kurusamy, Mark Berney, C. Mark Smales, Elizabeth M. Topp, Joanna F. McGouran, Steven Ferguson   +6 more
wiley   +2 more sources

Characteristics and Outcomes of Male Participants in a Multicenter Longitudinal Australian Study Cohort

Arthritis Care &Research, EarlyView.
Objective The aim of this study was to determine the differences in demographic, serologic, and clinical characteristics between male and female patients with systemic sclerosis (SSc) in an Australian cohort. Methods This was a retrospective observational study using data from the Australian Scleroderma Cohort Study.
Emily Lin, Dylan Hansen, Laura Ross, Gene‐Siew Ngian, Susanna Proudman, Gabor Major, Maryam Tabesh, Mandana Nikpour, Jennifer Walker, Lauren Host, Nava Ferdowsi, Alannah Quinlivan, Wendy Stevens, Joanne Sahhar, Diane Apostolopoulos   +14 more
wiley   +1 more source

Antioxidant effects of phosphodiesterase-5 inhibitors [PDF]

Cardiovascular Research, 2013
This letter refers to ‘The phosphodiesterase-5 inhibitor vardenafil reduces oxidative stress while reversing pulmonary arterial hypertension’ by Y.-F. Fan et al ., Cardiovascular Research (2013) 99, 395–403. Fan et al .1 have shown convincing results indicating that the phosphodiesterase-5 (PDE5) inhibitor vardenafil reduces oxidative stress and this
openaire   +2 more sources

Real‐World Safety and Effectiveness of JAK Inhibitors in Systemic Sclerosis: A Propensity‐Matched Study From the EUSTAR Cohort

Arthritis Care &Research, EarlyView.
Objective JAK inhibitors (JAKi) have shown promising effects in early‐phase studies of systemic sclerosis (SSc). We aimed to assess the safety and explore the effectiveness of JAKi compared to conventional immunosuppressants in SSc. Methods A longitudinal retrospective study of the European Scleroderma Trials and Research Group (EUSTAR) cohort was ...
Stefano Di Donato, Marie‐Elise Truchetet, Marco Minerba, Oliver Distler, Juan José Alegre Sancho, Yolanda Braun‐Moscovici, Christina Bergmann, Petros Sfikakis, Jeska K. de Vries‐Bouwstra, Murray Baron, Silvia Bellando‐Randone, Lorenzo Dagna, Christopher P. Denton, Madelon C. Vonk, Vanessa Smith, Ivan Castellvi, Gabriela Riemekasten, Andra Balanescu, Masataka Kuwana, Maria De Santis, Kamal Solanki, Anastas Batalov, Vahan Mukuchyan, Marco Matucci‐Cerinic, Yannick Allanore, Francesco Del Galdo, Michael Hughes, EUSTAR Collaborators   +27 more
wiley   +1 more source